| Docetaxel versus active symptom control for refractory oesophagogastric adenocarcinoma (COUGAR-02): an open-label, phase 3 randomised controlled trial HER Ford, A Marshall, JA Bridgewater, T Janowitz, FY Coxon, J Wadsley, ... The lancet oncology 15 (1), 78-86, 2014 | 673 | 2014 |
| Ordering of mutations in preinvasive disease stages of esophageal carcinogenesis JMJ Weaver, CS Ross-Innes, N Shannon, AG Lynch, T Forshew, ... Nature genetics 46 (8), 837-843, 2014 | 373 | 2014 |
| Mutational signatures in esophageal adenocarcinoma define etiologically distinct subgroups with therapeutic relevance M Secrier, X Li, N De Silva, MD Eldridge, G Contino, J Bornschein, ... Nature genetics 48 (10), 1131-1141, 2016 | 356 | 2016 |
| Gefitinib versus vinorelbine in chemotherapy-naive elderly patients with advanced non–small-cell lung cancer (INVITE): A randomized, phase II study L Crinò, F Cappuzzo, P Zatloukal, M Reck, M Pesek, JC Thompson, ... Journal of Clinical Oncology 26 (26), 4253-4260, 2008 | 271 | 2008 |
| Ramucirumab with cisplatin and fluoropyrimidine as first-line therapy in patients with metastatic gastric or junctional adenocarcinoma (RAINFALL): a double-blind, randomised … CS Fuchs, K Shitara, M Di Bartolomeo, S Lonardi, SE Al-Batran, ... The Lancet Oncology 20 (3), 420-435, 2019 | 227 | 2019 |
| The value of routine serum carcino-embryonic antigen measurement and computed tomography in the surveillance of patients after adjuvant chemotherapy for colorectal cancer I Chau, MJ Allen, D Cunningham, AR Norman, G Brown, HER Ford, ... Journal of clinical oncology 22 (8), 1420-1429, 2004 | 205 | 2004 |
| Multicentre cohort study to define and validate pathological assessment of response to neoadjuvant therapy in oesophagogastric adenocarcinoma F Noble, MA Lloyd, R Turkington, E Griffiths, M O'Donovan, JR O'Neill, ... Journal of British Surgery 104 (13), 1816-1828, 2017 | 102 | 2017 |
| Thymidylate synthase expression in advanced colorectal cancer predicts for response to raltitrexed DC Farrugia, HER Ford, D Cunningham, KD Danenberg, PV Danenberg, ... Clinical cancer research 9 (2), 792-801, 2003 | 85 | 2003 |
| Chemotherapy vs supportive care alone for relapsed gastric, gastroesophageal junction, and oesophageal adenocarcinoma: a meta-analysis of patient-level data T Janowitz, P Thuss-Patience, A Marshall, JH Kang, C Connell, N Cook, ... British journal of cancer 114 (4), 381-387, 2016 | 65 | 2016 |
| Combination of raltitrexed with other cytotoxic agents: rationale and preclinical observations AL Jackman, R Kimbell, HER Ford European Journal of Cancer 35, S3-S8, 1999 | 54 | 1999 |
| Venous thromboembolism in oesophago-gastric carcinoma: incidence of symptomatic and asymptomatic events following chemotherapy and surgery KE Rollins, CJ Peters, PM Safranek, H Ford, TP Baglin, RH Hardwick European Journal of Surgical Oncology (EJSO) 37 (12), 1072-1077, 2011 | 51 | 2011 |
| The palliative benefits of MVP (mitomycin C, vinblastine and cisplatin) chemotherapy in patients with malignant mesothelioma E Andreopoulou, PJ Ross, MER O'Brien, HER Ford, K Priest, T Eisen, ... Annals of oncology 15 (9), 1406-1412, 2004 | 46 | 2004 |
| COUGAR-02: A randomized phase III study of docetaxel versus active symptom control in advanced esophagogastric adenocarcinoma. H Ford, A Marshall, J Wadsley, FY Coxon, W Mansoor, JA Bridgewater, ... Journal of Clinical Oncology 31 (4_suppl), LBA4-LBA4, 2013 | 45 | 2013 |
| Phase III study of mitomycin-C with protracted venous infusion or circadian-timed infusion of 5-fluorouracil in advanced colorectal carcinoma TJ Price, PJ Ross, T Hickish, D Tait, AR Norman, HER Ford, G Middleton, ... Clinical colorectal cancer 3 (4), 235-242, 2004 | 43 | 2004 |
| Patterns of elevation of plasma 2′-deoxyuridine, a surrogate marker of thymidylate synthase (TS) inhibition, after administration of two different schedules of 5-fluorouracil … HER Ford, F Mitchell, D Cunningham, DC Farrugia, ME Hill, C Rees, ... Clinical cancer research 8 (1), 103-109, 2002 | 42 | 2002 |
| Phase I study of irinotecan and raltitrexed in patients with advanced astrointestinal tract adenocarcinoma HER Ford, D Cunningham, PJ Ross, S Rao, GW Aherne, TS Benepal, ... British journal of cancer 83 (2), 146-152, 2000 | 32 | 2000 |
| Molecular effects of Lapatinib in the treatment of HER2 overexpressing oesophago-gastric adenocarcinoma N De Silva, L Schulz, A Paterson, W Qain, M Secrier, E Godfrey, H Cheow, ... British journal of cancer 113 (9), 1305-1312, 2015 | 31 | 2015 |
| Authentication and characterisation of a new oesophageal adenocarcinoma cell line: MFD-1 E Garcia, A Hayden, C Birts, E Britton, A Cowie, K Pickard, M Mellone, ... Scientific reports 6 (1), 32417, 2016 | 28 | 2016 |
| B3-04: Gefitinib (IRESSA) versus vinorelbine in chemonaïve elderly patients with advanced non-small-cell lung cancer (INVITE): a randomized Phase II study L Crinò, P Zatloukal, M Reck, M Pesek, J Thomson, H Ford, F Hirsch, ... Journal of Thoracic Oncology 2 (8), S341, 2007 | 25 | 2007 |
| Trimodality therapy versus perioperative chemotherapy in the management of locally advanced adenocarcinoma of the oesophagus and oesophagogastric junction (Neo-AEGIS): an open … JV Reynolds, SR Preston, B O'Neill, MA Lowery, L Baeksgaard, T Crosby, ... The Lancet Gastroenterology & Hepatology 8 (11), 1015-1027, 2023 | 23 | 2023 |
Timothy PriceThe Queen Elizabeth Hospital and School of Medicine University of AdelaideVerified email at adelaide.edu.au
